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Abstract
The National Cancer Institute defines cancer as a group of related diseases characterized
by unimpeded cell division with metastatic abilities. Cells frequently mutate and potentially
become cancerous, but generally these cells are cleared by the immune system. The disease
state of cancer arises when the mutated cells evade the immune clearance, which indicates
medical intervention is required. Current therapies most commonly utilize chemotherapy,
radiation, or a combination of the two, however, alternative therapies are being developed such
as immunotherapies and oncolytic viruses (OVs). OVs cause a viral infection, clearing cancerous
cells through viral replication mechanisms, such as viral cytolysis, while simultaneously priming
the adaptive immune system to better recognize and clear infected cancer cells. OVs are also
capable of facilitating changes to the tumor microenvironment (TME), optimizing the immune
response. Certain characteristics are required of OVs, such as a large population immunologically
naïve to the infection, inability to cause serious disease in humans, and preferential replication
in cancerous cells. Tanapoxvirus (TPV) is currently being investigated as an effective OV. Most
of the world is immunologically naïve to the virus, which is isolated to the Tana River Valley in
Kenya. The infection is defined as self-limiting, and resolves approximately six weeks postinfection independent of treatment. Preferential replication in cancerous cells is not innate to
TPV; however, it can be induced by ablation of the thymidine kinase gene. The therapeutic
benefits of TPV have been observed in in vivo nude mouse models utilizing colorectal cancer,
triple negative breast cancer (TNBC), as well as melanoma. The TPV/∆66R/fliC viral recombinant
was effective in regression of induced colorectal cancer in a nude mouse model. The 66R ablation
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is the thymidine kinase gene, which increases preferential replication within cancerous cells, and
the fliC insertion will stimulate the innate immune response through interactions with Toll-like
receptor 5. In TNBC both the TPV/∆66R/CCL-2 and the TPV/∆66R/m-IL2 recombinants showed
significant regression in induced TNBC tumors on the nude mouse model. These mechanisms
function by recruiting macrophages at the site of infection and priming the T cells for increased
cancer cell recognition respectively. Finally the TPV/∆15L recombinant was able to show
regression in melanoma tumors in the nude mouse model by preventing the production of
interferon-1 (INF-1). An in vitro cell assay was conducted and indicated that INF-1 asserts a
greater antiproliferative effect than the type one INFs, so by preventing the production of this
cytokine an increase efficiency of viral replication will be observed. Finally, the TPV infection is
influenced by the TME through interactions with matrix metalloproteinase-9 (MMP-9).
Interactions with MMP-9 prevents viral replication from occurring by an unknown mechanism,
and preventing this interaction will increase the therapeutic effects TPV can assert. Future
studies will observe the effects of TPV in an immunocompetent mouse model, as well as the
potential of TPV as a treatment for pancreatic cancer. This research indicated that TPV has
immense potential as an OV for treatment of multiple different types of cancers, and it’s
therapeutic effects should continue to be investigated.
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INTRODUCTION
Cancer is defined, by the National Cancer Institute, as a group of related diseases
characterized by uninterrupted, invasive cell growth with the ability to invade other tissues in the
body. The National Cancer Institute estimates that in 2018, there will be 1,735,350 new
diagnoses of cancer with 609,640 cancer-related deaths in the United States alone. With cancer
having such a significant impact, treatment options have been a focal point of medical research.
Many different treatment models have been implemented, such as chemotherapy and radiation.
However, recent developments have allowed for utilization of the human body, through the
immune system, to clear these cancer cells. The immune system is responsible for clearing
abnormal cells from the body; however, cancerous cells are able to evade the immune response.
Capitalizing on the innate properties of the immune system, researchers have begun to develop
new treatment techniques for cancer.
Our body has been imbued with the ability to fight off foreign pathogens, as well as the
ability to recognize abnormal self-cells present within the body. The immune system can be
divided into two different sections, the innate and the adaptive immune system. The innate
immune system is the body’s generalized defense to combat disease. No specific pathogen is
being targeted by the innate immune system; instead conserved traits in many pathogens are
targets for the innate response. For example, lysozyme naturally observed in tears is capable of
lysing the cell wall of many different species of bacteria. This type of immune response allows
for the body to combat a wide array of pathogens without the time required to produce
specialized cell types, as observed in the adaptive immune response.
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The adaptive immune response is the body’s ability to target and clear specific pathogens
from the body. The adaptive immune response can be broken into two divisions, humoral and
cellular adaptive immunity. The humoral branch of the adaptive immune system is characterized
by recognizing and tagging pathogens for clearance. B cells are the primary cell associated with
this process. The presence of the pathogen will stimulate B cells to produce antibodies that will
bind to one specific epitope on that specific pathogen. After the infection subsides some B cells
will be converted to memory cells, which allows for faster recognition of the pathogen during
subsequent infections. The cellular response of the adaptive immune system is facilitated by T
cells, and these cells will interact with the antigens presented by other immune cells. This
interaction will cause the release of cytolytic proteins, or cytokines to recruit other immune cells,
depending on what type of T cell is involved in the interaction. Recent innovations have allowed
for potential cancer therapies that utilize the immune response to assist in the clearance of
cancerous cells.
Recently researchers have begun using viruses to activate the immune system to target
cancer cells. Due to the ability of cancer cells to evade the immune clearing mechanism, they act
as optimal sites of viral replication. This allows for the viral replication to proceed uninhibited,
producing a larger number of virion particles that are capable of infecting surrounding cancerous
cells. The viral infection also has the capability of increasing clearance of cancer cells by
promoting interaction of the immune cells. This is facilitated by immune cells recognizing viral
antigens present on the surface of infected cancer cells.
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CANCER THERAPY THROUGH ONCOLYTIC VIRUSES (OVs)
Only viruses that meet an essential criteria are potential candidates to be utilized in
effective oncolytic virotherapy. A crucial requirement of an effective OV is the ability for the virus
to preferentially replicate within cancerous cells, while not infecting the healthy cells. This is
referred to as the oncospecificity of the virus. Some viruses, such as some species of reovirus,
have the innate ability to preferentially replicate within cancerous cells due to imperfections in
the antiviral response of these cells (Conrad et al., 2015).
Other OVs can be genetically modified to increase the oncospecificity of the virus. For
example, viruses with a DNA genome require phosphorylated nucleotides for replication, and
ablation of the viral thymidine kinase gene will increase the oncospecificity of this type of virus.
The thymidine kinase gene produces a protein that allows the virus to convert thymidine into a
form suitable for incorporation to the viral progeny genome. Without this enzyme, the virus
relies on the uptake of a usable thymine nucleotide from the environment for replication. Since
cancerous cells are constantly undergoing replication, these cells have high levels of thymidine
kinase activity; therefore, these cells will have a surplus of usable nucleotides. Thus, the viral
particle will preferentially infect the cancerous cells for usable thymidine, which allows viral
replication to occur.

This preferential replication in cancerous cells due to thymidine

requirement results in an increased oncospecificity of viruses with an ablated thymidine kinase
gene (Twumasi et al., 2018).
Other intrinsic factors of a virus that influence its effectiveness as a potential therapeutic
agent include mode of transmission, infection mechanisms, and prevalence of the virus. An ideal
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OV will not be easily transmissible from the infected individual to others. Therefore, airborne
pathogens are not ideal candidates, because of the ease with which other people could become
infected. A second trait for an ideal OV is a self-limiting infection, implying a definitive end to the
infection, and no incorporation of the viral genome into the host genome.

Viral DNA

incorporation into the host genome would indicate a persistent infection that would affect the
patient for life.
Finally, an ideal characteristic of an OV, is that a majority of the target population for this
therapeutic agent is immunologically naïve. The prevalence of the virus in a particular area will
generally indirectly correlate with the proportion of the population that is naïve to the infection.
OVs tend to originate from a highly centralized area so that a very limited population have been
exposed to the viral infection. An individual who has never been exposed to the virus is
considered immunologically naïve because the immune system has not interacted with this
pathogen before. The naivety allows for the OV to have maximal therapeutic effect before it is
cleared by the immune system. However, after a host is exposed to a pathogen, the adaptive
immune system produces memory cells that are capable of identifying and clearing harmful
matter from the body exponentially faster. This implies that there is a limited use for each OV in
one individual, but one individual is capable of benefitting from the therapeutic effects with the
use of multiple OVs.
An individual OV is not a cure for cancer, but instead is one option in a wide selection of
potential treatments. The array of successful OVs that researchers have been developing come
from many different virus families, including the poxvirus family (Chaurasiya et al., 2018). OVs
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have been increasingly utilized as a potential treatment for cancer because these viruses are able
to combat cancer through numerous modes of action.
Viral Cytolysis
Through natural and engineered processes, viruses can employ a variety of mechanisms
to target cancer cells. The first mechanism being the naturally occurring cytolysis that is observed
at the end of viral infections. Viral infections will enter either the lytic or lysogenic cycle. The
lysogenic cycle is a period of time when the virus incorporates into the host genome, and will be
considered dormant, not actively replicating. This incorporation into the genome allows for the
virus to infect all of the daughter cells produced by the infected cell due to the incorporation of
the viral DNA into the host’s genome. Eventually the virus will exit the lysogenic cycle and enter
the lytic cycle, which is characterized by active viral replication. Not all viruses are capable of
entering the lysogenic cycle, but the lytic cycle can be observed in all viral infections. The end of
the lytic cycle is notated by the release of the progeny virion particles from the host cell due to
cell lysis. This is one of the innate mechanisms of viral infection that will allow for OVs to assist
in clearing cancerous cells from the body.
Priming the Adaptive Immune System
Although the immune system has the power to vanquish tumor cells, cancer cells are able
to evade the adaptive immune system. However, with OV therapy, cells infected with the virus
display antigenic markers to notify the immune system that a viral infection is underway within
the cell. The display of these antigens interacts with the adaptive immune cells and initiates the
clearing of the infected cells. To increase the rate of clearance of the infected cells, different
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transgenes, such as pro-apoptotic and immunostimulatory transgenes, can be introduced to the
genome of an OV (Chaurasiya et al., 2018). The insertion of these transgenes will cause the gene
product to be formed during viral replication. These protein products trigger cancer cell
apoptosis or signal immune system activity, which is how these genes assert their effect during
the infection. Activation of the adaptive immune system will also initiate the production and
release of cytokines, which are able to recruit other immune cells to the site of infection. The
production of cytokines attracts the T cells to intratumor locations, which has been associated
with better health outcomes for the patient (Twumasi et al., 2018). To fully assert their effects,
the adaptive immune cells must still overcome the immune suppression that is observed in the
tumor microenvironment (TME) due to the tumor (Twumasi et al., 2018).
Changes to TME
OV infection will cause the secretion of inflammatory cytokines that are capable of TME
remodeling and allow for the adaptive immune cells to function within the TME longer and cause
more tumor necrosis (Martin and Bell, 2018). Aside from triggering the immune response,
viruses also can evade the immune system, which allows for increase in replication time and a
subsequent increased viral load. A larger viral load increases the number of free virus particles,
released after cell lysis, that are able to infect surrounding tumor cells. As part of this process,
the OV can utilize some of the immunosuppressive characteristics of the tumor to its benefit.
Most cancerous cells do not respond to apoptotic signaling, which is beneficial to allow for
maximal viral replication without premature cell clearance due to the immune response
(Chaurasiya et al., 2018).

Not only do cancerous cells create an immunosuppressive
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environment, but they are also capable of evading adaptive immune responses by inhibiting the
communication between cancerous cells and immune cells. Infection by some OVs can reverse
this phenomenon, and allow for immune cells to better recognize cancerous cells and initiate
clearing these cells from the body by presentation of viral antigens during infection (Twumasi et
al., 2018). OVs are such a powerful tool because not only does the initial viral infection begins
lysis of the tumor cells, but the virus also primes the adaptive immune system to increase the
recognition and clearance rate of the cancerous cells.

TANAPOX VIRUS AS A POTENTIAL OV
The Poxviridae family is a very promising family of viruses to utilize for future oncolytic
virotherapies. Poxviruses are stable, allowing for these viruses to freely travel in the blood to
infect a wide array of cells, and initiate rapid cell lysis. Furthermore, poxviruses cause a selflimiting infection (Mundi et al, 2014). Poxviruses are also considered large genome viruses, which
allows for more ablation and insertion of genes without interfering with genes responsible for
viral replication within the cell. These genetic modifications can play many roles as noted earlier,
but most importantly allow for an increase in oncospeceficity that is not native to the Poxvirus
family (Conrad et al., 2015).
Tanapox virus (TPV), a species of the Poxvirus family, is a strong candidate as an OV
partially due to the large proportion of the population of the world naïve to infection by this virus.
The TPV species is located primarily in equatorial Africa, specifically to the Tana River Valley. In
the 1970’s, a study was conducted that indicated that TPV was isolated by comparing the serum
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concentrations of anti-TPV antibody from individuals from the Tana River valley and Tanzania.
The individuals from the Tana River valley showed varying concentrations of neutralizing
antibodies present within their blood, whereas those from Tanzania had very little to no
antibodies present (Manson-Bahr and Downie, 1973). This conclusion indicates that most of the
population outside of the Tana River Valley will be immunologically naïve for the TPV infection.
This trait appears to have persisted over time, and is still observed today. Only four known cases
of TPV infection have occurred in the United States, most of which occurred in research labs
utilizing the virus (Dhar et al., 2004). TPV infections are characterized by the formation of one or
two small nodules, fever, backaches, and severe headaches; these symptoms resolve within a
couple weeks (Dahr et al., 2004). TPV replication is limited to the location of the nodules, because
of decreased replication efficiency in higher temperatures observed at the bodies core; this may
be associated with the self-limiting characteristic of the TPV infection (Nazarian et al., 2007).
Furthermore, TPV is transmitted through contact with an open lesion, and therefore will have
limited ability to infect other individuals (Dahr et al., 2004). These characteristics make TPV a
promising virus for OV therapy. The next steps in development of TPV as a therapeutic agent is
the demonstration of the efficacy of TPV in tumor infection and size regression.
Tanapox Priming the Immune System
Specifically, TPV has been utilized in in vivo models of treatments for multiple cancer
types. Significant tumor size reduction was observed in colorectal cancer, triple negative breast
cancer, and melanoma using in vivo models treated with TPV recombinants. Since the poxviruses
generally lack oncospecificity, to facilitate the infection of tumor cells, the abalation of the
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thymidine kinase gene, 66R, was performed for recombinant TPV strains. For a colorectal cancer
study conducted by Conrad et al. (2015), the 2L gene was also ablated as this gene plays a role in
reducing inflammation and facilitates evasion of the immune response by infected cells. With
the 2L gene ablated, inflammation is observed at the site of infection, as well as an increase in
recognition of infected cells by the adaptive immune system. In attempts to increase the
clearance of the cancerous cells, the fliC transgene was introduced to the TPV genome, producing
a ∆66R/∆2L/fliC strain of the TPV. The fliC gene codes for the bacterial flagellin protein, which
will be produced during the viral replication process. The flagellin protein will interact with Tolllike receptor 5 (TLR 5), a portion of the innate immune system. When activated, TLR 5 causes
inflammation and activation of the innate immune response.
For experiments of the efficacy for colorectal cancer, the colorectal cell line HCT 116 was
selected due to the ability for the TPV recombinants to efficiently replicate within this cell line.
HCT 116 tumors were induced in nude mice, which lack a functional adaptive immune system.
These mice were deemed sufficient models for the TPV/∆66R/∆2L/fliC because the fliC protein
activates the innate immune system, which is still fully functional in nude mice. Once the HCT
116 tumors grew to a specified size, the mice received intratumor injections of either the vehicle,
or a TPV recombinant. The TPV/∆66R, TPV/∆2L, and TPV/∆2L/∆66R/fliC strains all displayed
significant regression in tumor size over the study. However, only the TPV/∆2L/∆66R/fliC virus
was able to show consistent significant reduction in tumor size, at multiple time points; this effect
was not observed in the other two recombinant viruses. Therefore, this study suggests that the
TPV/∆2L/∆66R/fliC strain was more effective, and able to reduce tumor size by two mechanisms.
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The first mechanism is the innate cytolytic processes associated with viral replication, which
caused cell cytolysis. The second is activation of the innate immune response by interactions of
the viral flagellin protein with the host TLR 5.
TPV recombinants have also been effective in targeting the highly aggressive triple
negative breast cancer (TBNC) cells. Effective treatment options for TBNC have been difficult to
identify due to the absence of estrogen and progesterone receptors, which are prime targets for
traditional breast cancer therapies. However, TPV recombinants have been shown to cause
cancer cell death in MDA-MB231 cells, a TNBC cell line. In a study conducted by Suryawanashi et
al. (2017), the TPV recombinants had the 66R gene ablated and had either an insertion of the mCCL2 or m-IL2 transgenes into the viral genome. CCL2 is a chemotactic chemokine that will recruit
immune cells, such as macrophages and dendritic cells, to the site of the tumor. However,
apparent species differences are observed between the human and mouse strain of the CCL2
gene. The human strain of the CCL-2 chemokine has been observed to promote tumor growth
and survival. This differs from the mouse CCL-2 gene, which was incorporated into the TPV
genome, and displayed no effect of prolonging the life span of in vitro MDA-MB231 cells. The
second cytokine is IL-2, which possesses dual functionality. IL-2 acts as a T cell growth factor,
initiating T cell maturation, in addition to activating tumor targeting macrophages. Based on
these properties, both the TPV/∆66R/m-CCL2 and the TPV/∆66R/m-IL2 recombinants were
produced to determine their efficiency in clearing the MDA-MB231 cells.
Both in vitro and in vivo studies were completed with these two TPV recombinants to
determine the efficacy of TPV as a treatment for TNBC. First, the in vitro infection efficiency was
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observed to determine which cell line would be utilized for the in vivo study as well as the role of
m-CCL2 on tumor growth and survival. The MDA-MB231 cell line was selected due to the
observation of efficient replication of TPV recombinants within these cells. Also, as stated earlier,
the study determined that m-CCL2 does not promote cancer cell survival. MDA-MB231 tumors
were induced in nude mice for the in vivo study to determine TPV recombinant functionality. The
in vivo model is only capable of evaluating the viral cytolytic mechanism of cancerous cell death,
because it lacks the functionality of the adaptive immune system. Both m-CCL2 and m-IL2 work
by activating the adaptive immune system; therefore, the observed cell lysis must be attributed
to the viral replication mechanism.

As designed, both recombinant strains of the TPV,

TPV/∆66R/m-CCL2 and TPV/∆66R/m-IL2, produced the desired effect to cause consistent and
significant tumor regression in the induced MDA-MB231 tumors. To determine the role of the
immunostimulatory transgenes, a follow up study will have to be conducted. This study will
require the utilization of a model that will allow for tumor induction in mice, without rejection,
while still having an intact adaptive immune system. Since both of these genes would increase
the adaptive immune response, it can be hypothesized that an even larger increase in tumor
regression would be observed in these new models.
However, not all recombinant viruses require the introduction of a transgene to increase
the oncolytic activity. Sometimes removal of a viral gene can induce tumor disrupting activity.
In a study conducted by Zhang et al. (2017) a, TPV recombinants with the ablated 15L gene have
been shown to significantly increase tumor regression in melanoma tumors induced in nude mice
without the insertion of a transgene. The 15L gene product mimics the neuregulin protein that
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interacts with receptors in the ERB receptor kinase family. The activation of these receptors
initiates a signal transduction pathway that results in the promotion of both DNA synthesis and
cell division. The increase in cell division due to the 15L gene product, appears to promote
increases in melanoma tumor size. However ablation of the 15L gene prevents the gene product
from being produced during viral infection while also reducing the amount of cell division
occurring during the infection. The ablation of the 15L gene is associated with increased
interferon-1 (INF-1) production.

Some types of INF have been observed to prevent

proliferative pathways in cancerous cells. The ablation of the 15L gene not only reduces
proliferation on its own, but the associated increase in INF-1 production further prevents cell
division.
Two independent experiments were conducted to determine the effect of the 15L
ablation during a TPV infection of the SK-MEL-3 strain of melanoma, as well as the role of INF-1
on cell proliferation. To examine the effects of the 15L gene ablation, an in vitro experiment was
conducted to determine in which cell line the TPV best replicated. The SK-MEL-3 melanoma cell
line was determined to be best suited for efficient replication and therefore, these cells were
utilized to induce tumors in nude mice. The SK-MEL-3 tumors were then treated with wild type
TPV, TPV/∆66R, TPV/∆15L, or TPV/∆15L/∆66R. Both viral strains were able to show significant
regressions in tumor size, the ∆66R and ∆15L single knockout viruses. However, only the ∆15L
virus was able to show a consistent significant regression at multiple time points.

The

TPV/∆15L/∆66R recombinant did not show any ability to significantly reduce the size of the
tumor. It is hypothesized that the ineffectiveness of the double knockout can be attributed to
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the increased replication time that was observed during the in vitro portion of this experiment.
The increase in replication time allows for fewer viral particles to be produced due to the slower
replication rate.
A second study was conducted by Zhang et al (2017) b, to determine the influence of
secondary infection components, such as INF-1, on the proliferation of melanoma cells. The
experiment analyzed the role of INF-1 and compared its effects to type one INFs, INF- and INF. INFs act as a mechanism of antiviral immune defense and will be produced by a virally infected
cell to act as a warning mechanism of viral presence. As stated earlier, the TPV/∆15L infection
increases the amount of INF-1 that is produced, which is less common and not as well
understood as the type one INFs. Type one interferons,  and , have shown to decrease the
proliferation of melanoma cells in vitro. To determine the antiproliferative effects of INF-1, an
in vitro experiment was conducted where SK-MEL-3 cells were grown in culture with either INF1, INF-, or INF-. Observations from the study indicated that INF-1 was more effective at
preventing SK-MEL-3 cell division than either INF- or INF-. A follow up study was conducted
to determine whether INF-1 was the factor responsible for the reduction in cell proliferation.
SK-MEL-3 cultures were infected with the TPV/∆15L virus, so that INF-1 would be produced by
the cells. After the allotted amount of time, anti-INF-1 antibody was introduced to neutralize
the INF to determine its effects on cell growth. After the addition of anti-INF-1 antibody, there
was an increased rate of cell survival and proliferation that was not observed during the initial
TPV/∆15L infection. This experiment confirms the role of INF-1 in limiting tumor cell division.
Tanapox Altering the TME
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OVs not only influence intracellular pathways, as has been noted thus far, but OVs also
are capable of interacting and altering the TME (Martin & Bell, 2018). Matrix metalloproteinase9 (MMP-9) is one component of the extracellular matrix found in the TME. The presence of MMP9 in melanoma indicates a poor prognosis, because the protein is associated with increased
tumor growth and metastasis. MMP-9 has the ability to inhibiting the viral infection, as observed
during TPV infections; however, the exact mechanism has yet to be determined. To determine
the impact that MMP-9 has on a TPV infection, an in vitro study was conducted. SK-MEL-3 cells
were infected with TPV with the fluorescent protein GFP (TPV/egfp), and grown in medium with
varying concentrations of the MMP-9 protein. It was shown that the presence of the MMP-9
protein is capable of dramatically reducing the amount of viral replication within these melanoma
cells by reducing the amount of fluorescence associated with the infection.
A follow-up study was conducted by Zhang and Essani (2017), to confirm the role of MMP9 in inhibition of viral replication. The study was repeated exactly as before, however an antiMMP-9 antibody was introduced at varying concentrations.

The addition of anti-MMP-9

antibody neutralized the MMP-9 protein and prevented its native effects on the viral infection.
As expected, the addition of the antibody allowed for a significant increase in viral replication,
which was observed as a correlated increase in GFP fluorescence. Once again, this confirms the
role of MMP-9 in inhibiting viral replication.
There are several proposed anti-viral mechanisms for MMP-9.

These include the

potential of the protein to cleave proteins necessary for the virus to enter the cell, prevention of
virus attachment to the cell, or alteration in the signaling process that occurs during TPV
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replication. The decrease in the TPV replication in the presence of MMP-9 is positively correlated
with a decrease in the amount of INF secreted by these cells. It is hypothesized that the
upregulation of MMP-9 inactivates the production of the INF cytokines, and therefore acts as a
protective factor for melanoma cells by allowing for uninhibited tumor cell replication. These
examples illustrate that the interaction of the OV and the TME is crucial in determining the
therapeutic effectiveness of an OV.
Conclusion
TPV has been associated with a regression in tumor size for a variety of different
cancerous cell lines through a different mechanisms. The amount of variance in treatment
strategies with TPV indicate strong potential as a future OV. This variance is associated with the
fact that the TPV genome is quite large, allowing for transgene insertion, and creating multiple
different potential mechanisms for tumor clearance. In tandem with the large portion of the
world’s population that is immunologically naïve, the therapeutic potential of TPV warrants
further investigation. Due to the difficulty in treating cancer and the limited potential of a single
OV as a treatment, TPV could be a great addition to the collection of OVs that are being utilized
to combat cancer. Future experiments will utilize the TPV recombinant viruses for treatment of
tumors induced in immunocompetent models to observe the effects of the immunostimulatory
transgenes.
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